05 May 2022 – Congratulations to Neuromagen Pharma Ltd. on their recent Orphan Drug Designation for AGS-499, its lead drug candidate. AGS-499 has shown significant effectiveness in delaying the onset and progression of Amyotrophic Lateral Sclerosis (ALS). PLC acted as the US Agent and submitted the application on behalf of Neuromagen to the US FDA.
22 February 2023 – PLC congratulates ARS Pharmaceuticals on their recent reacquisition of the European marketing rights to neffy®. Regulatory and clinical development of neffy has been supported by PLC in the US and overseas since program inception. neffy is a needle-free Epinephrine treatment for Type I allergic reactions including anaphylaxis. NDA and MAA reviews
With our partner in Europe, PLC continues to provide Regulatory support for the development of ARS-1. ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for NeffyTM (ARS-1; epinephrine nasal spray) Agreement will give access to millions at risk for severe allergic reaction to new pain-free delivery method for